KCM
ATYR

Kathmere Capital Management’s aTyr Pharma ATYR Stock Holding History

Kathmere Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10
Closed – – 417
2020
Q4 		$0 Hold
10
– – ﹤0.01% 455
2020
Q3 		$0 Buy
+10
New +$41 ﹤0.01% 400

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Kathmere Capital Management's ATYR Position: Q1 2021 in Review

Kathmere Capital Management sold out of aTyr Pharma (ATYR) in Q1 2021, closing a stake of 10 shares.

Kathmere Capital Management first reported a position in ATYR in Q3 2020 and held it in 2 quarters. The position peaked at $0 in Q4 2020. 25 funds tracked by Wall St. Rank hold ATYR as of Q1 2021.

  • Kathmere Capital Management reported no remaining aTyr Pharma position as of Q1 2021 after selling out during the quarter.
  • Kathmere Capital Management sold 10 aTyr Pharma shares in Q1 2021.
  • Kathmere Capital Management first reported a position in aTyr Pharma in Q3 2020 and held it in 2 quarters.
  • Kathmere Capital Management's aTyr Pharma position peaked at $0 in Q4 2020.
  • 25 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2021.

Based on Kathmere Capital Management's 13F filing for Q1 2021, filed 7 May 2021.